URIS
LIVE

Serial Number

79430358

Owner

STIMVIA

Attorney

Cathleen E. Stadecker

Filing Date

Jul 4, 2025

Add to watchlist:

No watchlists yet
View on USPTO

URIS Trademark

Serial Number: 79430358

URIS is a trademark filed by STIMVIA on July 4, 2025. The trademark is classified under Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

STIMVIA

Technologická 376/5, Pustkovec

Entity Type: 98

Trademark Details

Filing Date

July 4, 2025

Registration Date

Not Registered

Goods & Services

Electrodes and devices for neurostimulation for scientific and research purposes; Electrodes and devices for neuromodulation and electroceuticals treatment for scientific and research purposes; Downloadable and recorded computer software for use in the design and use of medical instruments and devices used in neuromodulation and electroceuticals treatment and therapy

Design, engineering, research, development and testing services for medical, scientific and technological products in the field of neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Design and development of medical instruments and devices for use in neuromodulation and electroceuticals treatment and therapy; Technology research in the field of medical instruments and devices for use in neuromodulation and electroceuticals treatment and therapy; Medical and scientific research services in the field of neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Medical and scientific research in the fields of urology, neurology, gynecology, infertility, overactive bladder, neurodegenerative diseases, and chronic diseases using neuromodulation and electroceuticals treatment and therapy; Providing medical and scientific research information in the fields of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Research and development of technology in the field of healthcare and medical devices, namely, in the field of neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Development of technology in the field of medical instruments and devices for neuromodulation and electroceuticals treatment and therapy; Design and development of computer software; Software as a service (SAAS) services featuring software for use in the design and use of medical instruments and devices used in neuromodulation and electroceuticals treatment and therapy; Providing temporary use of on-line non-downloadable software for use in the design and use of medical instruments and devices used in neuromodulation and electroceuticals treatment and therapy

Medical apparatus and instruments used for neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Medical devices used for neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Electrodes for medical use used for neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Medical electrodes and medical devices for use in neuromodulation, electro-stimulation and electroceuticals treatment and therapy; Medical instruments and devices for use in electroceuticals and neuromodulation treatment and therapy; Medical devices, namely, pulse generators for neurostimulation

Medical services in the field of neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Healthcare services in the nature of neuromodulation and electroceuticals treatment in the field of urology, neurology, gynecology, infertility, neurodegenerative diseases and overactive bladder, and of chronic diseases using neuromodulation treatment and therapy; Medical services in the fields of urology, neurology, gynecology, infertility, neurodegenerative diseases, overactive bladder, and chronic diseases using electroceuticals and neuromodulation treatment and therapy; Medical consultancy; Providing medical information in the fields of urology, neurology, gynecology, infertility, neurodegenerative diseases, overactive bladder, and chronic diseases using electroceuticals and neuromodulation treatment and therapy; Medical treatment of low urinary tract disfunction, Parkinson's diseases, Alzheimer's diseases, bowel disfunction, epilepsy, migraine and infertility using electroceuticals and neuromodulation treatment and therapy; Rental of medical instruments and devices for use in electroceuticals and neuromodulation therapy

Filing History

NOTIFICATION OF FINAL REFUSAL EMAILED
Apr 15, 2026 GNFN
FINAL REFUSAL E-MAILED
Apr 15, 2026 GNFR
FINAL REFUSAL WRITTEN
Apr 15, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 14, 2026 TROA
REFUSAL PROCESSED BY IB
Mar 26, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 6, 2026 RFCS
REFUSAL PROCESSED BY MPU
Mar 6, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 6, 2026 RFCR
NON-FINAL ACTION WRITTEN
Feb 5, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 31, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 30, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 30, 2026 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 12, 2025 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 14, 2025 REPR